FDA approves Mimrylo for treatment of rare blood cancer

The U.S. Food and Drug Administration (FDA) has approved Mimrylo for the treatment of polycythemia vera, a rare, chronic and slowly progressing blood cancer. STAT News reported the decision made on Friday.

Developer and sale of the drug

The active ingredient in Mimrylo is rusfertide, developed by the biotechnology company Protagonist Therapeutics. Japanese pharmaceutical company Takeda will sell the drug under the brand name Mimrylo.

More current news is available on the UA.News Telegram channel Telegram.

Weekly administration

Mimrylo is administered as an injection once a week. According to STAT News, the drug is a new type of therapy for people with polycythemia vera.

Polycythemia vera causes excessive production of red blood cells. As a result, patients’ blood becomes thicker, increasing the risk of life-threatening heart attacks, strokes and blood clots. The FDA approved Mimrylo specifically for the treatment of this disease.